Vertex Pharmaceuticals Incorporated

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1989-01-01

Employees: 5.4K

Market Cap: $123.9B

Website: http://www.vrtx.com

Clinical Trials

Pharmacokinetics and Safety Assessment of VX-121/Tezacaftor/Deutivacaftor in Participants With Moderate Hepatic Impairment

Phase 1

Completed

Conditions: Cystic Fibrosis

Interventions: Drug: VX-121/TEZ/D-IVA

First Posted Date: 2022-06-29

Last Posted Date: 2023-03-30

Lead Sponsor: Vertex Pharmaceuticals Incorporated

Target Recruit Count: 16

Registration Number: NCT05437120

Locations: 🇺🇸
Clinical Pharmacology of Miami, LLC, Miami, Florida, United States
🇺🇸
GCP Research, Saint Petersburg, Florida, United States

Evaluation of VX-121/Tezacaftor/Deutivacaftor in Cystic Fibrosis (CF) Participants 1 Through 11 Years of Age

Phase 3

Recruiting

Conditions: Cystic Fibrosis

Interventions: Drug: VX-121/TEZ/D-IVA

First Posted Date: 2022-06-16

Last Posted Date: 2024-11-18

Lead Sponsor: Vertex Pharmaceuticals Incorporated

Target Recruit Count: 210

Registration Number: NCT05422222

Locations: 🇺🇸
UPMC Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States
🇦🇺
Women & Children's Hospital, North Adelaide, Australia
🇺🇸
Children's Hospital of Orange County, Orange, California, United States

and more 31 locations

A Microneurography (MNG) Study of VX-150 in Healthy Participants

Phase 1

Completed

Conditions: Pain

Interventions: Drug: Placebo
Drug: VX-150

First Posted Date: 2022-06-14

Last Posted Date: 2022-10-14

Lead Sponsor: Vertex Pharmaceuticals Incorporated

Target Recruit Count: 45

Registration Number: NCT05418712

Locations: 🇬🇧
MAC Clinical Research, Manchester, United Kingdom

Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Transfusion-Dependent β-Thalassemia (TDT)

Phase 3

Recruiting

Conditions: Thalassemia
Genetic Diseases, Inborn
Beta-Thalassemia
Hematologic Diseases
Hemoglobinopathies

Interventions: Biological: CTX001

First Posted Date: 2022-05-02

Last Posted Date: 2024-10-17

Lead Sponsor: Vertex Pharmaceuticals Incorporated

Target Recruit Count: 15

Registration Number: NCT05356195

Locations: 🇺🇸
SCRI at the Children's Hospital at TriStar Centennial, Nashville, Tennessee, United States
🇨🇦
The Hospital for Sick Children, Toronto, Canada
🇩🇪
Universitätsklinikum Düsseldorf Hospital Duesseldorf, Düsseldorf, Germany

and more 3 locations

A Phase 1 Dose Escalation Study of Oral VX-708 in Healthy Participants

Phase 1

Completed

Conditions: Acute Pain

Interventions: Drug: VX-708
Drug: Placebo

First Posted Date: 2022-04-26

Last Posted Date: 2023-05-15

Lead Sponsor: Vertex Pharmaceuticals Incorporated

Target Recruit Count: 100

Registration Number: NCT05347394

Locations: 🇬🇧
MAC Clinical Research, Manchester, United Kingdom

Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Severe Sickle Cell Disease (SCD)

Phase 3

Recruiting

Conditions: Hydroxyurea Intolerance
Sickle Cell Disease
Hydroxyurea Failure
Hemoglobinopathies
Hematological Diseases

Interventions: Biological: CTX001

First Posted Date: 2022-04-15

Last Posted Date: 2024-10-17

Lead Sponsor: Vertex Pharmaceuticals Incorporated

Target Recruit Count: 15

Registration Number: NCT05329649

Locations: 🇺🇸
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸
Atrium Health Levine Children's Hospital, Charlotte, North Carolina, United States
🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States

and more 4 locations

Study to Evaluate Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) Long-term Safety and Efficacy in Subjects Without F508del

Phase 3

Active, not recruiting

Conditions: Cystic Fibrosis

Interventions: Drug: ELX/TEZ/IVA
Drug: IVA

First Posted Date: 2022-04-15

Last Posted Date: 2024-05-07

Lead Sponsor: Vertex Pharmaceuticals Incorporated

Target Recruit Count: 297

Registration Number: NCT05331183

Locations: 🇦🇹
Medizinische Universität Innsbruck, Innsbruck, Austria
🇧🇪
Cliniques Universitaires de Bruxelles Hopital Erasme, Brussels, Belgium
🇫🇷
CHU Marseille - Hopital Nord, Marseille, France

and more 78 locations

A Phase 1 Dose Escalation Study to Evaluate Safety and Pharmacokinetics (PK) of VX-840 in Healthy Participants

Phase 1

Completed

Conditions: APOL1-mediated Kidney Disease

Interventions: Drug: VX-840
Drug: Placebo

First Posted Date: 2022-04-12

Last Posted Date: 2022-12-08

Lead Sponsor: Vertex Pharmaceuticals Incorporated

Target Recruit Count: 88

Registration Number: NCT05324410

Locations: 🇺🇸
ICON Lenexa, Lenexa, Kansas, United States

Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1- Mediated Proteinuric Kidney Disease

Phase 2

Recruiting

Conditions: Proteinuric Kidney Disease

Interventions: Drug: VX-147
Drug: Placebo

First Posted Date: 2022-04-06

Last Posted Date: 2024-12-19

Lead Sponsor: Vertex Pharmaceuticals Incorporated

Target Recruit Count: 466

Registration Number: NCT05312879

Locations: 🇺🇸
Kings County Hospital, Brooklyn, New York, United States
🇺🇸
Prime Clinical Research Inc - Lewisville, Lewisville, Texas, United States
🇺🇸
Alabama Kidney Research, Alabaster, Alabama, United States

and more 291 locations

Evaluation of Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Cystic Fibrosis Subjects Without an F508del Mutation

Phase 3

Completed

Conditions: Cystic Fibrosis

Interventions: Other: Placebo (matched to ELX/TEZ/IVA)
Drug: ELX/TEZ/IVA
Other: Placebo (matched to IVA)
Drug: IVA

First Posted Date: 2022-03-10

Last Posted Date: 2024-08-01

Lead Sponsor: Vertex Pharmaceuticals Incorporated

Target Recruit Count: 307

Registration Number: NCT05274269

Locations: 🇨🇦
McGill University Health Centre, Glen Site, Montreal Children's Hospital, Montreal, Canada
🇨🇿
Fakultni nemocnice v Motole, Praha 5, Czechia
🇫🇷
Hopital Cochin, Paris, France

and more 87 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy